Comirnaty

Raxtozinameran [COVID-19 mRNA vaccine (nucleoside modified)].

The vaccine is a clear to slightly opalescent (10 mcg)/white to off-white (30 mcg) frozen dispersion (pH: 6.9-7.9).
1 dose (0.3 mL) contains 10 micrograms or 30 micrograms of raxtozinameran, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles).
This is a single dose or a multidose vial with a blue cap (10 mcg)/grey cap (30 mcg). Do not dilute prior to use.
One single dose vial contains 1 dose of 0.3 mL, see Dosage & Administration and Special Precautions for Disposal and Other Handling under Cautions for Usage.
One multidose vial (2.25 mL) contains 6 doses of 0.3 mL, see Dosage & Administration and Special Precautions for Disposal and Other Handling under Cautions for Usage.
Raxtozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5).
Excipients/Inactive Ingredients: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159), 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), Cholesterol, Trometamol, Trometamol hydrochloride, Sucrose, Water for injections.

Pharmacotherapeutic group: Vaccines, viral vaccines. ATC code: J07BN01.
Pharmacology: Pharmacodynamics: Mechanism of action: The nucleoside-modified messenger RNA in Comirnaty is formulated in lipid nanoparticles, which enable delivery of the non-replicating RNA into host cells to direct transient expression of the SARS-CoV-2 Santigen. The mRNA codes for membrane-anchored, full-length S with two-point mutations within the central helix. Mutation of these two amino acids to proline locks S in an antigenically preferred prefusion conformation. The vaccine elicits both neutralising antibody and cellular immune responses to the spike (S) antigen, which may contribute to protection against COVID-19.
Efficacy: Omicron-adapted Comirnaty: Immunogenicity in participants 12 years of age and older - after the booster (fourth dose): In an analysis of a subset from Study 5, 105 participants 12 to 17 years of age, 297 participants 18 through 55 years of age, and 286 participants 56 years of age and older who had previously received a 2-dose primary series and booster dose with Comirnaty received a booster (fourth dose) of Comirnaty Original/Omicron BA.4-5. In participants 12 through 17 years of age, 18 through 55 years of age, and 56 years of age and older, 75.2%, 71.7% and 61.5% were positive for SARS-CoV-2 at baseline, respectively.
Analyses of 50% neutralizing antibody titres (NT50) against Omicron BA.4-5 and against reference strain among participants 56 years of age and older who received a booster (fourth dose) of Comirnaty Original/Omicron BA.4-5 in Study 5 compared to a subset of participants from Study 4 who received a booster (fourth dose) of Comirnaty demonstrated superiority of Comirnaty Original/Omicron BA.4-5 to Comirnaty based on geometric mean ratio (GMR) and noninferiority based on difference in seroresponse rates with respect to anti-Omicron BA.4-5 response, and noninferiority of anti-reference strain immune response based on GMR (Table 1).
Analyses of NT50 against Omicron BA.4/BA.5 among participants 18 through 55 years of age compared to participants 56 years of age and older who received a booster (fourth dose) of Comirnaty Original/Omicron BA.4-5 in Study 5 demonstrated noninferiority of anti-Omicron BA.4-5 response among participants 18 through 55 years of age compared to participants 56 years of age and older for both GMR and difference in seroresponse rates (Table 1).
The study also assessed the level of NT50 of the anti-Omicron BA.4-5 SARS-CoV-2 and reference strains pre-vaccination and 1 month after vaccination in participants who received a booster (fourth dose) (Table 2). (See Tables 1 and 2.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Comirnaty: Study 2 is a multicentre, multinational, Phase 1/2/3 randomised, placebo-controlled, observer-blind dose-finding, vaccine candidate selection and efficacy study in participants 12 years of age and older. Randomisation was stratified by age: 12 to 15 years of age, 16 to 55 years of age, or 56 years of age and older, with a minimum of 40% of participants in the ≥56-year stratum. The study excluded participants who were immunocompromised and those who had previous clinical or microbiological diagnosis of COVID-19. Participants with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrolment, were included as were participants with known stable infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV).
Efficacy in participants 16 years of age and older - after 2 doses: In the Phase 2/3 portion of Study 2, based on data accrued through 14 November 2020, approximately 44,000 participants were randomised equally and were to receive 2 doses of the initially approved COVID-19 mRNA Vaccine or placebo. The efficacy analyses included participants that received their second vaccination within 19 to 42 days after their first vaccination. The majority (93.1%) of vaccine recipients received the second dose 19 days to 23 days after Dose 1. Participants are planned to be followed for up to 24 months after Dose 2, for assessments of safety and efficacy against COVID-19. In the clinical study, participants were required to observe a minimum interval of 14 days before and after administration of an influenza vaccine in order to receive either placebo or COVID-19 mRNA Vaccine. In the clinical study, participants were required to observe a minimum interval of 60 days before or after receipt of blood/plasma products or immunoglobulins within through conclusion of the study in order to receive either placebo or COVID-19 mRNA Vaccine.
The population for the analysis of the primary efficacy endpoint included, 36,621 participants 12 years of age and older (18,242 in the COVID-19 mRNA Vaccine group and 18,379 in the placebo group) who did not have evidence of prior infection with SARS-CoV-2 through 7 days after the second dose. In addition, 134 participants were between the ages of 16 to 17 years of age (66 in the COVID-19 mRNA Vaccine group and 68 in the placebo group) and 1,616 participants 75 years of age and older (804 in the COVID-19 mRNA Vaccine group and 812 in the placebo group).
At the time of the primary efficacy analysis, participants had been followed for symptomatic COVID-19 for in total 2,214 person-years for the COVID-19 mRNA Vaccine and in total 2,222 person-years in the placebo group.
There were no meaningful clinical differences in overall vaccine efficacy in participants who were at risk of severe COVID-19 including those with 1 or more comorbidities that increase the risk of severe COVID-19 (e.g., asthma, body mass index (BMI) ≥30 kg/m², chronic pulmonary disease, diabetes mellitus, hypertension).
The vaccine efficacy information is presented in Table 3. (See Table 3.)

Click on icon to see table/diagram/image

Efficacy of COVID-19 mRNA Vaccine in preventing first COVID-19 occurrence from 7 days after Dose 2 compared to placebo was 94.6% (95% confidence interval of 89.6% to 97.6%) in participants 16 years of age and older with or without evidence of prior infection with SARS-CoV-2.
Additionally, subgroup analyses of the primary efficacy endpoint showed similar efficacy point estimates across genders, ethnic groups, and participants with medical comorbidities associated with high risk of severe COVID-19.
Updated efficacy analyses were performed with additional confirmed COVID-19 cases accrued during blinded placebo-controlled follow-up, representing up to 6 months after Dose 2 in the efficacy population.
The updated vaccine efficacy information is presented in Table 4. (See Table 4.)

Click on icon to see table/diagram/image

In the updated efficacy analysis, efficacy of COVID-19 mRNA Vaccine in preventing first COVID-19 occurrence from 7 days after Dose 2 compared to placebo was 91.1% (95% CI of 88.8% to 93.0%) during the period when Wuhan/Wild type and Alpha variants were the predominant circulating strains in participants in the evaluable efficacy population with or without evidence of prior infection with SARS-CoV-2.
Additionally, the updated efficacy analyses by subgroup showed similar efficacy point estimates across sexes, ethnic groups, geography and participants with medical comorbidities and obesity associated with high risk of severe COVID-19.
Efficacy against severe COVID-19: Updated efficacy analyses of secondary efficacy endpoints supported benefit of the COVID-19 mRNA Vaccine in preventing severe COVID‑19.
As of 13 March 2021, vaccine efficacy against severe COVID-19 is presented only for participants with or without prior SARS-CoV-2 infection (Table 5) as the COVID-19 case counts in participants without prior SARS-CoV-2 infection were the same as those in participants with or without prior SARS-CoV-2 infection in both the COVID-19 mRNA Vaccine and placebo groups. (See Table 5.)

Click on icon to see table/diagram/image

Efficacy and immunogenicity in adolescents 12 to 15 years of age - after 2 doses: In an initial analysis of Study 2 in adolescents 12 to 15 years of age (representing a median follow-up duration of >2 months after Dose 2) without evidence of prior infection, there were no cases in 1,005 participants who received the vaccine and 16 cases out of 978 who received placebo. The point estimate for efficacy is 100% (95% confidence interval 75.3, 100.0). In participants with or without evidence of prior infection there were 0 cases in the 1,119 who received vaccine and 18 cases in 1,110 participants who received placebo. This also indicates the point estimate for efficacy is 100% (95% confidence interval 78.1, 100.0).
Updated efficacy analyses were performed with additional confirmed COVID-19 cases accrued during blinded placebo-controlled follow-up, representing up to 6 months after Dose 2 in the efficacy population.
In the updated efficacy analysis of Study 2 in adolescents 12 to 15 years of age without evidence of prior infection, there were no cases in 1,057 participants who received the vaccine and 28 cases out of 1,030 who received placebo. The point estimate for efficacy is 100% (95% confidence interval 86.8, 100.0) during the period when Alpha variant was the predominant circulating strain. In participants with or without evidence of prior infection there were 0 cases in the 1,119 who received vaccine and 30 cases in 1,109 participants who received placebo. This also indicates the point estimate for efficacy is 100% (95% confidence interval 87.5, 100.0).
In Study 2, an analysis of SARS-CoV-2 neutralising titres 1 month after Dose 2 was conducted in a randomly selected subset of participants who had no serological or virological evidence of past SARS-CoV-2 infection up to 1 month after Dose 2, comparing the response in adolescents 12 to 15 years of age (n=190) to participants 16 to 25 years of age (n=170).
The ratio of the geometric mean titres (GMT) in the 12 to 15 years of age group to the 16 to 25 years of age group was 1.76, with a 2-sided 95% CI of 1.47 to 2.10. Therefore, the 1.5-fold noninferiority criterion was met as the lower bound of the 2-sided 95% CI for the geometric mean ratio [GMR] was >0.67.
10 mcg: Immunogenicity in children 5 to 11 years of age (i.e., 5 to less than 12 years of age) - after the booster (fourth dose): In an analysis of a subset from Study 6, 103 participants 5 to 11 years of age who had previously received a 2-dose primary series and booster dose with Comirnaty received a booster (fourth dose) of Comirnaty Original/Omicron BA.4-5. Results include immunogenicity data from a comparator subset of participants 5 to 11 years of age in Study 3 who received 3 doses of Comirnaty. In participants 5 to 11 years of age who received a fourth dose of Comirnaty Original/Omicron BA.4-5 and participants 5 to 11 years of age who received a third dose of Comirnaty, 57.3% and 58.4% were positive for SARS-CoV-2 at baseline, respectively.
The immune response 1 month after a booster dose (fourth dose), Comirnaty Original/Omicron BA.4-5 elicited generally similar Omicron BA.4/BA.5-specific neutralizing titres compared with the titres in the comparator group who received 3 doses of Comirnaty. Comirnaty Original/Omicron BA.4-5 also elicited similar reference strain-specific titres compared with the titres in the comparator group.
The vaccine immunogenicity results after a booster dose in participants 5 to 11 years of age are presented in Table 6. (See Table 6.)

Click on icon to see table/diagram/image

Efficacy and immunogenicity in children 5 to 11 years of age (i.e., 5 to less than 12 years of age) - after 2 doses: Study 3 is a Phase 1/2/3 study comprised of an open-label vaccine dose-finding portion (Phase 1) and a multicentre, multinational, randomised, saline placebo-controlled, observer-blind efficacy portion (Phase 2/3) that has enrolled participants 5 to 11 years of age. The majority (94.4%) of randomised vaccine recipients received the second dose 19 days to 23 days after Dose 1.
Initial descriptive vaccine efficacy results in children 5 to 11 years of age without evidence of prior SARS-CoV-2 infection are presented in Table 7. No cases of COVID-19 were observed in either the vaccine group or the placebo group in participants with evidence of prior SARS-CoV-2 infection. (See Table 7.)

Click on icon to see table/diagram/image

Pre-specified hypothesis-driven efficacy analysis was performed with additional confirmed COVID-19 cases accrued during blinded placebo-controlled follow-up, representing up to 6 months after Dose 2 in the efficacy population.
In the efficacy analysis of Study 3 in children 5 to 11 years of age without evidence of prior infection, there were 10 cases in 2,703 participants who received the vaccine and 42 cases out of 1,348 who received placebo. The point estimate for efficacy is 88.2% (95% confidence interval 76.2, 94.7) during the period when Delta variant was the predominant circulating strain. In participants with or without evidence of prior infection there were 12 cases in the 3,018 who received vaccine and 42 cases in 1,511 participants who received placebo. The point estimate for efficacy is 85.7% (95% confidence interval 72.4, 93.2).
In Study 3, an analysis of SARS-CoV-2 50% neutralising titres (NT50) 1 month after Dose 2 in a randomly selected subset of participants demonstrated effectiveness by immunobridging of immune responses comparing children 5 to 11 years of age (i.e., 5 to less than 12 years of age) in the Phase 2/3 part of Study 3 to participants 16 to 25 years of age in the Phase 2/3 part of Study 2 who had no serological or virological evidence of past SARS CoV-2 infection up to 1 month after Dose 2, meeting the prespecified immunobridging criteria for both the geometric mean ratio (GMR) and the seroresponse difference with seroresponse defined as achieving at least 4-fold rise in SARS-CoV-2 NT50 from baseline (before Dose 1).
The GMR of the SARS-CoV-2 NT50 1 month after Dose 2 in children 5 to 11 years of age (i.e., 5 to less than 12 years of age) to that of young adults 16 to 25 years of age was 1.04 (2-sided 95% CI: 0.93, 1.18). Among participants without prior evidence of SARS-CoV-2 infection up to 1 month after Dose 2, 99.2% of children 5 to 11 years of age and 99.2% of participants 16 to 25 years of age had a seroresponse at 1 month after Dose 2. The difference in proportions of participants who had seroresponse between the 2 age groups (children - young adult) was 0.0% (2-sided 95% CI: -2.0%, 2.2%). This information is presented in Table 8. (See Table 8.)

Click on icon to see table/diagram/image

Immunogenicity in children 5 to 11 years of age (i.e. 5 to less than 12 years of age) - after booster dose: A booster dose of Comirnaty was given to 401 randomly selected participants in Study 3. Effectiveness of a booster dose in ages 5 to 11 is inferred by immunogenicity. The immunogenicity of this was assessed through NT50 against the reference strain of SARS-CoV-2 (USA_WA1/2020). Analyses of NT50 1 month after the booster dose compared to before the booster dose demonstrated a substantial increase in GMTs in individuals 5 through 11 years of age who had no serological or virological evidence of past SARS-CoV-2 infection up to 1 month after the dose 2 and the booster dose. This analysis is summarized in Table 9. (See Table 9.)

Click on icon to see table/diagram/image

30 mcg: Immunogenicity in participants 18 years of age and older - after booster dose: Effectiveness of a booster dose of Comirnaty was based on an assessment of 50% neutralising antibody titres (NT50) against SARS-CoV-2 (USA_WA1/2020) in Study 2. In this study, the booster dose was administered 5 to 8 months (median 7 months) after the second dose. In Study 2, analyses of NT50 1 month after the booster dose compared to 1 month after the primary series in individuals 18 through 55 years of age who had no serological or virological evidence of past SARS-CoV-2 infection up to 1 month after the booster vaccination demonstrated noninferiority for both geometric mean ratio (GMR) and difference in seroresponse rates. Seroresponse for a participant was defined as achieving a ≥4-fold rise in NT50 from baseline (before primary series). These analyses are summarized in Table 10. (See Table 10.)

Click on icon to see table/diagram/image

Relative vaccine efficacy in participants 16 years of age and older - after booster dose: An interim efficacy analysis of Study 4, a placebo-controlled booster study performed in approximately 10,000 participants 16 years of age and older who were recruited from Study 2, evaluated confirmed COVID-19 cases accrued from at least 7 days after booster vaccination up to a data cut-off date of 5 October 2021, which represents a median of 2.5 months post-booster follow-up. The booster dose was administered 5 to 13 months (median 11 months) after the second dose. Vaccine efficacy of the Comirnaty booster dose after the primary series relative to the placebo booster group who only received the primary series dose was assessed.
The relative vaccine efficacy information for participants 16 years of age and older without prior evidence of SARS-CoV-2 infection is presented in Table 11. Relative vaccine efficacy in participants with or without evidence of prior SARS-CoV-2 infection was 94.6% (95% confidence interval of 88.5% to 97.9%), similar to that seen in those participants without evidence of prior infection. Primary COVID-19 cases observed from 7 days after booster vaccination were 7 primary cases in the Comirnaty group, and 124 primary cases in the placebo group. (See Table 11.)

Click on icon to see table/diagram/image

Immunogenicity of a booster dose following primary vaccination with another authorised COVID-19 vaccine: Effectiveness of a Comirnaty booster dose (30 mcg) in individuals who completed primary vaccination with another authorised COVID-19 vaccine (heterologous booster dose) is inferred from immunogenicity data from an independent National Institutes of Health (NIH) study phase ½ open-label clinical trial (NCT04889209) conducted in the United States. In this study, adults (range 19 to 80 years of age) who had completed primary vaccination with Moderna 100 mcg 2-dose series (N=51, mean age 54±17), Janssen single dose (N=53, mean age 48±14), or Comirnaty 30 mcg 2-dose series (N=50, mean age 50±18) at least 12 weeks prior to enrolment and who reported no history of SARS-CoV-2 infection received a booster dose of Comirnaty (30 mcg). The boost with Comirnaty induced a 36, 12, and 20 GMR-fold rise in neutralising titres following the Janssen, Moderna, and Comirnaty primary doses, respectively.
Heterologous boosting with Comirnaty was also evaluated in the CoV-BOOST study (EudraCT 2021-002175-19), a multicentre, randomised, controlled, phase 2 trial of third dose booster vaccination against COVID-19, in which 107 adult participants (median age 71 years of age, interquartile range 54 to 77 years of age) were randomised at least 70 days post 2 doses of AstraZeneca COVID-19 Vaccine. After the AstraZeneca COVID‑19 Vaccine primary series, pseudovirus (wild-type), neutralising antibody NT50 GMR-fold change increased 21.6-fold with heterologous Comirnaty booster (n=95).
Immunogenicity in participants >55 years of age - after a booster dose (fourth dose) of Comirnaty (30 mcg): In an interim analysis of a subset from Study 4 (Substudy E), 305 participants >55 years of age who had completed a series of 3 doses of Comirnaty received Comirnaty (30 mcg) as a booster dose (fourth dose) 5 to 12 months after receiving Dose 3. For the Immunogenicity subset data see Table 12.
Immunogenicity in participants 18 to ≤55 years of age - after a booster dose (fourth dose) of Comirnaty (30 mcg): In Substudy D [a subset from Study 2 (Phase 3) and Study 4 (Phase 3)], 325 participants 18 to ≤55 years of age who had completed 3 doses of Comirnaty received Comirnaty (30 mcg) as a booster dose (fourth dose) 90 to 180 days after receiving Dose 3. For the Immunogenicity subset data see Table 12. (See Table 12.)

Click on icon to see table/diagram/image

Pharmacokinetics: Not applicable.
Toxicology: Preclinical Safety Data: Non-clinical data reveal no special hazard for humans based on conventional studies of repeat dose toxicity and reproductive and developmental toxicity.
General toxicity: Rats intramuscularly administered Comirnaty (receiving 3 full human doses once weekly, generating relatively higher levels in rats due to body weight differences) demonstrated some injection site oedema and erythema and increases in white blood cells (including basophils and eosinophils) consistent with an inflammatory response as well as vacuolation of portal hepatocytes without evidence of liver injury. All effects were reversible.
Genotoxicity/Carcinogenicity: Neither genotoxicity nor carcinogenicity studies were performed. The components of the vaccine (lipids and mRNA) are not expected to have genotoxic potential.
Reproductive toxicity: Reproductive and developmental toxicity were investigated in rats in a combined fertility and developmental toxicity study where female rats were intramuscularly administered Comirnaty prior to mating and during gestation (receiving 4 full human doses that generate relatively higher levels in rat due to body weight differences, spanning between pre-mating day 21 and gestational day 20). SARS-CoV-2 neutralising antibody responses were present in maternal animals from prior to mating to the end of the study on postnatal day 21 as well as in foetuses and offspring. There were no vaccine-related effects on female fertility, pregnancy, or embryo-foetal or offspring development. No Comirnaty data are available on vaccine placental transfer or excretion in milk.

Comirnaty Omicron XBB.1.5 (10 or 30 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years (10 mcg) and individuals 12 years of age and older (30 mcg).

Posology: For individuals who have previously been vaccinated with a COVID-19 vaccine, Comirnaty Omicron XBB.1.5 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine.
10 mcg: Children 5 to 11 years of age (i.e. 5 to less than 12 years of age): Comirnaty Omicron XBB.1.5 (10 micrograms)/dose dispersion for injection is administered intramuscularly as a single dose of 0.3 mL for children 5 to 11 years of age regardless of prior COVID-19 vaccination status (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Severely immunocompromised aged 5 years and older: Additional doses may be administered to individuals who are severely immunocompromised in accordance with national recommendations (see Precautions).
Comirnaty Omicron XBB.1.5 (10 micrograms)/dose should be used only for children 5 to 11 years of age.
Paediatric population: There are paediatric formulations available for infants and children aged 6 months to 4 years. For details, refer to the monograph for other formulations.
The safety and efficacy of the vaccine in infants aged less than 6 months have not yet been established.
30 mcg: Individuals 12 years of age and older: Comirnaty Omicron XBB.1.5 (30 micrograms)/dose is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Severely immunocompromised aged 12 years and older: Additional doses may be administered to individuals who are severely immunocompromised in accordance with national recommendations (see Precautions).
Paediatric population: There are paediatric formulations available for infants aged 6 months and above and children below 12 years of age. For details, refer to the monograph for other formulations.
The safety and efficacy of the vaccine in infants aged less than 6 months have not yet been established.
Elderly population: No dose adjustment is required in elderly individuals ≥65 years of age.
Method of administration: Comirnaty Omicron XBB.1.5 (10 micrograms/30 micrograms)/dose dispersion for injection should be administered intramuscularly (see Special Precautions for Disposal and Other Handling under Cautions for Usage). Do not dilute prior to use.
The preferred site is the deltoid muscle of the upper arm (see Special Precautions for Disposal and Other Handling under Cautions for Usage).
Do not inject the vaccine intravascularly, subcutaneously or intradermally.
The vaccine should not be mixed in the same syringe with any other vaccines or medicinal products.
For precautions to be taken before administering the vaccine, see Precautions.
For instructions regarding thawing, handling and disposal of the vaccine, see Special Precautions for Disposal and Other Handling under Cautions for Usage.
Single dose vials: Single dose vials of Comirnaty Omicron XBB.1.5 contain 1 dose of 0.3 mL of vaccine.
Withdraw a single 0.3 mL dose of Comirnaty Omicron XBB.1.5.
Discard vial and any excess volume.
Do not pool excess vaccine from multiple vials.
Multidose vials: Multidose vials of Comirnaty Omicron XBB.1.5 contain 6 doses of 0.3 mL of vaccine. In order to extract 6 doses from a single vial, low dead-volume syringes and/or needles should be used. The low dead-volume syringe and needle combination should have a dead volume of no more than 35 microlitres. If standard syringes and needles are used, there may not be sufficient volume to extract a sixth dose from a single vial.
Irrespective of the type of syringe and needle: Each dose must contain 0.3 mL of vaccine.
If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume.
Do not pool excess vaccine from multiple vials.

Overdose data is available from 52 study participants included in the clinical trial that due to an error in dilution received 58 micrograms of Comirnaty. The vaccine recipients did not report an increase in reactogenicity or adverse reactions.
In the event of overdose, monitoring of vital functions and possible symptomatic treatment is recommended.

Hypersensitivity to the active substance or to any of the excipients listed in Description.

Do not dilute.
10 mcg: For 5 to 11 years of age.
30 mcg: For 12 years of age and older.

Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Hypersensitivity and anaphylaxis: Events of anaphylaxis have been reported. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine.
Close observation for at least 30 minutes is recommended following vaccination. No further dose of the vaccine should be given to those who have experienced anaphylaxis after a prior dose of Comirnaty.
Myocarditis and pericarditis: There is an increased risk of myocarditis and pericarditis following vaccination with Comirnaty. These conditions can develop within just a few days after vaccination, and have primarily occurred within 14 days. They have been observed more often after the second vaccination, and more often in younger males. Available data suggest that the course of myocarditis and pericarditis following vaccination is not different from myocarditis or pericarditis in general (see Adverse Reactions).
Healthcare professionals should be alert to the signs and symptoms of myocarditis and pericarditis. Vaccinees (including parents or caregivers) should be instructed to seek immediate medical attention if they develop symptoms indicative of myocarditis or pericarditis such as (acute and persisting) chest pain, shortness of breath, or palpitations following vaccination.
Healthcare professionals should consult guidance and/or specialists to diagnose and treat this condition.
Anxiety-related reactions: Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress‐related reactions (e.g., dizziness, palpitations, increases in heart rate, alterations in blood pressure, paraesthesia, hypoaesthesia and sweating) may occur in association with the vaccination process itself. Stress-related reactions are temporary and resolve on their own. Individuals should be advised to bring symptoms to the attention of the vaccination provider for evaluation. It is important that precautions are in place to avoid injury from fainting.
Concurrent illness: Vaccination should be postponed in individuals suffering from acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination.
Thrombocytopenia and coagulation disorders: As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Immunocompromised individuals: The efficacy and safety of the vaccine has not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of Comirnaty Omicron XBB.1.5 maybe lower in immunocompromised individuals.
Duration of protection: The duration of protection afforded by the vaccine is unknown as it is still being determined by ongoing clinical trials.
Limitations of vaccine effectiveness: As with any vaccine, vaccination with Comirnaty Omicron XBB.1.5 may not protect all vaccine recipients. Individuals may not be fully protected until 7 days after their vaccination.
Effects on Ability to Drive and Use Machines: Comirnaty Omicron XBB.1.5 has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under Adverse Reactions may temporarily affect the ability to drive or use machines.

Pregnancy: No data are available yet regarding the use of Comirnaty Omicron XBB.1.5 during pregnancy.
However, a large amount of observational data from pregnant women vaccinated with the initially approved Comirnaty vaccine during the second and third trimester have not shown an increase in adverse pregnancy outcomes. While data on pregnancy outcomes following vaccination during the first trimester are presently limited, no increased risk for miscarriage has been seen. Animal studies do not indicate director indirect harmful effects with respect to pregnancy, embryo/foetal development, parturition or post-natal development (see Pharmacology: Toxicology: Preclinical Safety Data under Actions). Based on data available with other vaccine variants, Comirnaty Omicron XBB.1.5 can be used during pregnancy.
Breast-feeding: No data are available yet regarding the use of Comirnaty Omicron XBB.1.5 during breast-feeding.
However, no effects on the breast-fed newborn/infant are anticipated since the systemic exposure of breast-feeding woman to the vaccine is negligible. Observational data from women who were breast-feeding after vaccination with the initially approved Comirnaty vaccine have not shown a risk for adverse effects in breast-fed newborns/infants. Comirnaty Omicron XBB.1.5 can be used during breast-feeding.
Fertility: Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see Pharmacology: Toxicology: Preclinical Safety Data under Actions).

Summary of safety profile: The safety of Comirnaty Omicron XBB.1.5 is inferred from safety data of the prior Comirnaty vaccine.
Adolescents 12 to 15 years of age - after 2 doses: In an analysis of long-term safety follow-up in Study 2, 2,260 adolescents (1,131 Comirnaty and 1,129 placebo) were 12 to 15 years of age. Of these, 1,559 adolescents (786 Comirnaty and 773 placebo) have been followed for ≥4 months after the second dose. The safety evaluation in Study 2 is ongoing.
The overall safety profile of Comirnaty in adolescents 12 to 15 years of age was similar to that seen in participants 16 years of age and older. The most frequent adverse reactions in adolescents 12 to 15 years of age that received 2 doses were injection site pain (>90%), fatigue and headache (>70%), myalgia and chills (>40%), arthralgia and pyrexia (>20%).
Participants 16 years of age and older - after 2 doses: In Study 2, a total of 22,026 participants 16 years of age or older received at least 1 dose of the initially approved Comirnaty vaccine and a total of 22,021 participants 16 years of age or older received placebo (including 138 and 145 adolescents 16 and 17 years of age in the vaccine and placebo groups, respectively). A total of 20,519 participants 16 years of age or older received 2 doses of Comirnaty.
At the time of the analysis of Study 2 with a data cut-off of 13 March 2021 for the placebo-controlled blinded follow-up period up to the participants' unblinding dates, a total of 25,651 (58.2%) participants (13,031 Comirnaty and 12,620 placebo) 16 years of age and older were followed up for ≥4 months after the second dose. This included a total of 15,111 (7,704 Comirnaty and 7,407 placebo) participants 16 to 55 years of age and a total of 10,540 (5,327 Comirnaty and 5,213 placebo) participants 56 years of age and older.
The most frequent adverse reactions in participants 16 years of age and older that received 2 doses were injection site pain (>80%), fatigue (>60%), headache (>50%), myalgia (>40%), chills (>30%), arthralgia (>20%), pyrexia and injection site swelling (>10%) and were usually mild or moderate in intensity and resolved within a few days after vaccination. A slightly lower frequency of reactogenicity events was associated with greater age.
The safety profile in 545 participants 16 years of age and older receiving Comirnaty, that were seropositive for SARS-CoV-2 at baseline, was similar to that seen in the general population.
Booster dose following primary vaccination with another authorised COVID-19 vaccine: In 5 independent studies on the use of a Comirnaty booster dose in individuals who had completed primary vaccination with another authorised COVID-19 vaccine (heterologous booster dose), no new safety issues were identified.
Omicron-adapted Comirnaty: Participants 12 years of age and older - after a booster dose of Comirnaty Original/Omicron BA.4-5 (fourth dose): In a subset from Study 5 (Phase 2/3), 107 participants 12 to 17 years of age, 313 participants 18 to 55 years of age and 306 participants 56 years of age and older who had completed 3 doses of Comirnaty, received a booster (fourth dose) of Comirnaty Original/Omicron BA.4-5 (15/15 mcg) 5.4 to 16.9 months after receiving Dose 3. Participants who received a booster (fourth dose) of Comirnaty Original/Omicron BA.4-5 had a median follow-up time of at least 1.5 months.
The overall safety profile for the Comirnaty Original/Omicron BA.4-5 booster (fourth dose) was similar to that seen after 3 doses. The most frequent adverse reactions in participants 12 years of age and older were injection site pain (>60%), fatigue (>50%), headache (>40%), muscle pain (>20%), chills (>10%),and joint pain (>10%).
Comirnaty 10 mcg: Children 5 to 11 years of age (i.e., 5 to less than 12 years of age) - after 2 doses: In Study 3, a total of 3,109 children 5 to 11 years of age received at least 1 dose of the initially approved Comirnaty vaccine 10 mcg and a total of 1,538 children 5 to 11 years of age received placebo. At the time of the analysis of Study 3 Phase 2/3 with data up to the cut-off date of 20 May 2022, 2,206 (1,481 Comirnaty 10 mcg and 725 placebo) children have been followed for ≥4 months after the second dose in the placebo-controlled blinded follow-up period. The safety evaluation in Study 3 is ongoing.
The overall safety profile of Comirnaty in participants 5 to 11 years of age was similar to that seen in participants 16 years of age and older. The most frequent adverse reactions in children 5 to 11 years of age that received 2 doses were injection site pain (>80%), fatigue (>50%), headache (>30%), injection site redness and swelling (≥20%), myalgia, chills, and diarrhoea (>10%).
Children 5 to 11 years of age (i.e., 5 to less than 12 years of age) - after booster dose: In a subset from Study 3, a total of 401 children 5 to 11 years of age received a booster dose of Comirnaty 10 mcg at least 5 months (range of 5 to 9 months) after completing the primary series. The analysis of the Study 3 Phase 2/3 subset is based on data up to the cut-off date of 22 March 2022 (median follow-up time of 1.3 months).
The overall safety profile for the booster dose was similar to that seen after the primary course. The most frequent adverse reactions in children 5 to 11 years of age were injection site pain (>70%), fatigue (>40%), headache (>30%), myalgia, chills, injection site redness and swelling (>10%).
Participants 16 years of age and older - after booster dose: A subset from Study 2 Phase 2/3 participants of 306 adults 18 to 55 years of age who completed the original Comirnaty 2-dose course, received a booster dose of Comirnaty approximately 6 months (range of 4.8 to 8.0 months) after receiving Dose 2. Overall, participants who received a booster dose, had a median follow-up time of 8.3 months (range 1.1 to 8.5 months) and 301 participants had been followed for ≥6 months after the booster dose to the cut-off date (22 November 2021).
The overall safety profile for the booster dose was similar to that seen after 2 doses. The most frequent adverse reactions in participants 18 to 55 years of age were injection site pain (>80%), fatigue (>60%), headache (>40%), myalgia (>30%), chills and arthralgia (>20%).
In Study 4, a placebo-controlled booster study, participants 16 years of age and older recruited from Study 2 received a booster dose of Comirnaty (5,081 participants), or placebo (5,044 participants) at least 6 months after the second dose of Comirnaty. Overall, participants who received a booster dose, had a median follow-up time of 2.8 months (range 0.3 to 7.5 months) after the booster dose in the blinded placebo-controlled follow up period to the cut-off date (8 February 2022). Of these, 1,281 participants (895 Comirnaty and 386 placebo) have been followed for ≥4 months after the booster dose of Comirnaty. No new adverse reactions of Comirnaty were identified.
Omicron-adapted Comirnaty: Children 5 to 11 years of age (i.e., 5 to less than 12 years of age) - after the booster (fourth dose): In a subset from Study 6 (Phase 3), 113 participants 5 to 11 years of age who had completed 3 doses of Comirnaty, received a booster (fourth dose) of Comirnaty Original/Omicron BA.4-5 (5/5 mcg) 2.6 to 8.5months after receiving Dose 3. Participants who received a booster (fourth dose) of Comirnaty Original/Omicron BA.4-5 had a median follow-up time of at least 1.6 months.
The overall safety profile for the Comirnaty Original/Omicron BA.4-5 booster (fourth dose) was similar to that seen after 3 doses. The most frequent adverse reactions in participants 5 to 11 years of age were injection site pain (>60%), fatigue (>40%), headache (>20%), and muscle pain (>10%).
Comirnaty 30 mcg: Participants 12 years of age and older - after booster dose: The safety of a booster dose of Comirnaty in participants 12 years of age and older is inferred from safety data from studies of a booster dose of Comirnaty in participants 16 years of age and older.
A subset from Study 2 Phase 2/3 participants of 306 adults 18 to 55 years of age who completed the original Comirnaty 2-dose course, received a booster dose of Comirnaty approximately 6 months (range of 4.8 to 8.0 months) after receiving Dose 2. Overall, participants who received a booster dose, had a median follow-up time of 8.3 months (range 1.1 to 8.5 months) and 301 participants had been followed for ≥6 months after the booster dose to the cut-off date (22 November 2021).
The overall safety profile for the booster dose was similar to that seen after 2 doses. The most frequent adverse reactions in participants 18 to 55 years of age were injection site pain (>80%), fatigue (>60%), headache (>40%), myalgia (>30%), chills and arthralgia (>20%).
In Study 4, a placebo-controlled booster study, participants 16 years of age and older recruited from Study 2 received a booster dose of Comirnaty (5,081 participants), or placebo (5,044 participants) at least 6 months after the second dose of Comirnaty. Overall, participants who received a booster dose, had a median follow-up time of 2.8 months (range 0.3 to 7.5 months) after the booster dose in the blinded placebo-controlled follow-up period to the cut-off date (8 February 2022). Of these, 1,281 participants (895 Comirnaty and 386 placebo) have been followed for ≥4 months after the booster dose of Comirnaty. No new adverse reactions of Comirnaty were identified.
Participants 12 years of age and older - after subsequent booster doses: The safety of a booster dose of Comirnaty in participants 12 years of age and older is inferred from safety data from studies of a booster dose of Comirnaty in participants 18 years of age and older.
A subset of 325 adults 18 to ≤55 years of age who had completed 3 doses of Comirnaty, received a booster (fourth dose) of Comirnaty 90 to 180 days after receiving Dose 3. Participants who received a booster (fourth dose) of Comirnaty had a median follow-up time of 1.4 months up to a data cut-off date of 11 March 2022. The most frequent adverse reactions in these participants were injection site pain (>70%), fatigue (>60%), headache (>40%), myalgia and chills (>20%), and arthralgia (>10%).
In a subset from Study 4 (Phase 3), 305 adults >55 years of age who had completed 3 doses of Comirnaty, received a booster (fourth dose) of Comirnaty 5 to 12 months after receiving Dose 3. Participants who received a booster (fourth dose) of Comirnaty had a median follow-up time of at least 1.7 months up to a data cut-off date of 16 May 2022. The overall safety profile for the Comirnaty booster (fourth dose) was similar to that seen after the Comirnaty booster (third dose). The most frequent adverse reactions in participants >55 years of age were injection site pain (>60%), fatigue (>40%), headache (>20%), myalgia and chills (>10%).
Tabulated list of adverse reactions from clinical studies of Comirnaty and Comirnaty Original/Omicron BA.4-5 and post-authorisation experience of Comirnaty in individuals 5 years of age and older (10 mcg) and 12 years of age and older (30 mcg): Adverse reactions observed during clinical studies are listed as follows according to the following frequency categories: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000), Very rare (<1/10,000), Not known (cannot be estimated from the available data). (See Table 13.)

Click on icon to see table/diagram/image

Description of selected adverse reactions: Myocarditis and pericarditis: The increased risk of myocarditis after vaccination with Comirnaty is highest in younger males (see Precautions).
Two large European pharmacoepidemiological studies have estimated the excess risk in younger males following the second dose of Comirnaty. One study showed that in a period of 7 days after the second dose there were about 0.265 (95% CI 0.255-0.275) extra cases of myocarditis in 12-29 year old males per 10,000 compared to unexposed persons. In another study, in a period of 28 days after the second dose there were 0.56 (95% CI 0.37-0.74) extra cases of myocarditis in 16-24 year old males per 10,000 compared to unexposed persons.
Limited data indicate that the risk of myocarditis and pericarditis after vaccination with Comirnaty in children aged 5 to 11 years seems lower than in ages 12 to 17 years.
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

No interaction studies have been performed.
Concomitant administration of Comirnaty Omicron XBB.1.5 with other vaccines has not been studied.

Incompatibilities: This medicinal product must not be mixed with other medicinal products.
Special Precautions for Disposal and Other Handling: Handling instructions: Comirnaty Omicron XBB.1.5 should be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared dispersion. (See Table 14.)

Click on icon to see table/diagram/image

Instructions Applicable to Both Single and Multidose Vials: Vial verification of Comirnaty Omicron XBB 1.5 (10 micrograms)/dose dispersion for injection (children 5 to 11 years) or (30 micrograms)/dose dispersion for injection (12 years and older): Verify that the vial has a blue (10 mcg)/grey (30 mcg) plastic cap and the product name is Comirnaty Omicron XBB.1.5 (10 micrograms)/dose dispersion for injection.
Check whether the vial is a single dose vial or a multidose vial and follow the applicable handling instructions as follows.
If the vial has another product name on the label, make reference to the monograph for that formulation.
Handling prior to use of Comirnaty Omicron XBB 1.5 (10 micrograms)/dose dispersion for injection (children 5 to 11 years) or (30 micrograms)/dose dispersion for injection (12 years and older): If the single or multidose vial is stored frozen it must be thawed prior to use. Frozen vials should be transferred to an environment of 2°C to 8°C to thaw. Ensure vials are completely thawed prior to use.
Single dose vials: A 10-vial pack of single dose vials may take 2 hours to thaw.
Multidose vials: A 10-vial pack of multidose vials may take 6 hours to thaw.
Upon moving vials to 2°C to 8°C storage, update the expiry date on the carton.
Unopened vials can be stored for up to 10 weeks at 2°C to 8°C.
Alternatively, individual frozen vials may be thawed for 30 minutes at temperatures up to 30°C.
Prior to use, the unopened vial can be stored for up to 12 hours at temperatures up to 30°C. Thawed vials can be handled in room light conditions.
Gently mix by inverting vials 10 times prior to use. Do not shake.
Prior to mixing, the thawed dispersion may contain white to off-white opaque amorphous particles.
After mixing, the vaccine should present as a white to off-white dispersion with no particulates visible. Do not use the vaccine if particulates or discolouration are present.
Preparation of individual 0.3 mL doses of Comirnaty Omicron XBB 1.5 (10 micrograms)/dose dispersion for injection (children 5 to 11 years) or (30 micrograms)/dose dispersion for injection (12 years and older): Single dose vials: Withdraw a single 0.3 mL dose of vaccine.
Discard vial and any excess volume.
Multidose vials: Multidose vials contain 6 doses of 0.3 mL each.
Using aseptic technique, cleanse the vial stopper with a single-use antiseptic swab.
Withdraw 0.3 mL of Comirnaty Omicron XBB.1.5 for children aged 5 to 11 years (10 mcg) or 12 years and older (30 mcg).
Low dead-volume syringes and/or needles should be used in order to extract 6 doses from a single vial. The low dead-volume syringe and needle combination should have a dead volume of no more than 35 microlitres.
If standard syringes and needles are used, there may not be sufficient volume to extract a sixth dose from a single vial.
Each dose must contain 0.3 mL of vaccine.
If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume.
Record the appropriate date/time on the vial. Discard any unused vaccine 12 hours after first puncture.
Disposal: Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Store in a freezer at -90°C to -60°C.
Store in the original package in order to protect from light.
During storage, minimise exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.
For storage conditions after thawing and first opening, see Shelf Life as follows.
Shelf Life: Unopened vial: Frozen vial: 12 months (10 mcg) or 18 months (30 mcg) when stored at -90°C to -60°C.
The vaccine will be received frozen at -90°C to -60°C. Frozen vaccine can be stored either at -90°C to -60°C or 2°C to 8°C upon receipt.
Single dose vials: When stored frozen at -90°C to -60°C, 10-vial packs of single dose vials of the vaccine can be thawed at 2°C to 8°C for 2 hours or individual vials can be thawed at room temperature (up to 30°C) for 30 minutes.
Multidose vials: When stored frozen at -90°C to -60°C, 10-vial packs of multidose vials of the vaccine can be thawed at 2°C to 8°C for 6 hours or individual vials can be thawed at room temperature (up to 30°C) for 30 minutes.
Thawed vial: 10 weeks storage and transportation at 2°C to 8°C within the 12-month (10 mcg) or 18-month (30 mcg) shelf life.
Upon moving the vaccine to 2°C to 8°C storage, the updated expiry date must be written on the outer carton and the vaccine should be used or discarded by the updated expiry date. The original expiry date should be crossed out.
If the vaccine is received at 2°C to 8°C it should be stored at 2°C to 8°C. The expiry date on the outer carton should have been updated to reflect the refrigerated expiry date and the original expiry date should have been crossed out.
Prior to use, the unopened vials can be stored for up to 12 hours at temperatures between 8°C and 30°C.
Thawed vials can be handled in room light conditions.
Once thawed, the vaccine should not be re-frozen.
Handling of temperature excursions during refrigerated storage: Stability data indicate that the unopened vial is stable for up to 10 weeks when stored at temperatures from -2°C to 2°C, within the 10-week storage period between 2°C and 8°C.
Stability data indicate the vial can be stored for up to 24 hours at temperatures of 8°C to 30°C, including up to 12 hours following first puncture.
This information is intended to guide healthcare professionals only in case of temporary temperature excursion.
Opened vial: Chemical and physical in-use stability has been demonstrated for 12 hours at 2°C to 30°C, which includes up to 6 hours transportation time. From a microbiological point of view, unless the method of opening precludes the risks of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

Vaccines, Antisera & Immunologicals

J07BN01 - covid-19, RNA-based vaccine ; Belongs to the class of covid-19 vaccines.

S